Heart Failure Subtypes and Cardiomyopathies in Women
暂无分享,去创建一个
Anubha Agarwal | U. Elkayam | A. Beale | C. Lam | E. Hsich | E. DeFilippis | T. Martyn
[1] Giuseppe Famularo,et al. Transthyretin amyloid cardiomyopathy. , 2023, The American journal of the medical sciences.
[2] P. Ponikowski,et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.
[3] Akshay S. Desai,et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial , 2021, The Lancet.
[4] M. Mack,et al. Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. , 2021, JACC. Heart failure.
[5] C. Rapezzi,et al. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS. , 2021, JACC. Heart failure.
[6] D. Holmes,et al. Sex Differences in Outcomes Following Left Atrial Appendage Closure. , 2021, Mayo Clinic proceedings.
[7] M. Costanzo,et al. Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice , 2021, Circulation. Heart failure.
[8] F. Zannad,et al. Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure , 2021, JACC. Heart failure.
[9] S. Blankenberg,et al. Sex-Related Clinical Characteristics and Outcomes of Patients Undergoing Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. , 2021, JACC. Cardiovascular interventions.
[10] V. Kouranos,et al. Cardiac sarcoidosis: state-of-the-art review , 2021, Heart.
[11] P. Heerdt,et al. Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction. , 2020, Chest.
[12] J. Lasala,et al. Sociodemographic differences in utilization and outcomes for temporary cardiovascular mechanical support in the setting of cardiogenic shock. , 2020, American heart journal.
[13] C. Yancy,et al. Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review , 2020, European journal of heart failure.
[14] Y. Ko,et al. Gender Differences in Mortality After Left Ventricular Assist Device Implant: A Causal Mediation Analysis Approach. , 2020, ASAIO journal.
[15] Z. Fayad,et al. Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[16] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.
[17] D. Burkhoff,et al. Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis due to Val122Ile Mutation: Insights from Non-Invasive Pressure-Volume Analysis. , 2020, Journal of cardiac failure.
[18] A. Volgman,et al. Sex Differences in Takotsubo Syndrome: A Narrative Review. , 2020, Journal of women's health.
[19] Adam Castaño,et al. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges , 2020, Heart Failure Reviews.
[20] Song Zhao,et al. Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF". , 2020, Circulation.
[21] Sanjiv J. Shah,et al. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. , 2020, JACC. Heart failure.
[22] Mark P. MacEachern,et al. Extracorporeal Life Support in Pregnancy: A Systematic Review , 2020, Journal of the American Heart Association.
[23] R. Falk,et al. Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.
[24] L. Lund,et al. Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease , 2020, European journal of heart failure.
[25] S. Solomon,et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.
[26] M. Wheeler,et al. Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. , 2020, JACC. Heart failure.
[27] S. Patil,et al. Gender Differences in Rates of Arrhythmias, Cardiac Implantable Electronic Devices, and Diagnostic Modalities Among Sarcoidosis Patients , 2020, Cureus.
[28] E. Depasquale,et al. Heart Transplantation Outcomes in Adults with Postpartum Cardiomyopathy. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] M. Clowse,et al. Antirheumatic medications in pregnancy and breastfeeding. , 2020, Current opinion in rheumatology.
[30] G. Kararigas,et al. Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF: JACC Review Topic of the Week. , 2020, Journal of the American College of Cardiology.
[31] M. Barton,et al. Heart Failure With Preserved Ejection Fraction in Women , 2020, JACC. Basic to translational science.
[32] D. Hilfiker-Kleiner,et al. Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. , 2020, Cardiovascular research.
[33] S. Solomon,et al. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials , 2020, European journal of heart failure.
[34] M. Dweck,et al. Sex differences in aortic stenosis: from pathophysiology to treatment , 2020, Expert review of cardiovascular therapy.
[35] S. Goland,et al. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[36] Brandon C. Benefield,et al. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension , 2020, ESC heart failure.
[37] S. Solomon,et al. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. , 2019, JACC. Heart failure.
[38] C. Grines,et al. Use of Impella heart pump for management of women with peripartum cardiogenic shock , 2019, Clinical cardiology.
[39] R. Falk,et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. , 2019, JACC. Heart failure.
[40] H. D. den Ruijter,et al. Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction , 2019, Front. Endocrinol..
[41] A. Petrie,et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. , 2019, Circulation.
[42] M. Michels,et al. Sex differences in hypertrophic cardiomyopathy: new insights , 2019, Current opinion in cardiology.
[43] J. Lindenfeld,et al. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. , 2019, JACC. Heart failure.
[44] Y. Naka,et al. Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. , 2019, JACC. Heart failure.
[45] J. Mariani,et al. Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis. , 2019, JACC. Heart failure.
[46] M. Kürtüncü,et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.
[47] E. Hsich,et al. Heart Failure with Reduced Ejection Fraction in Women: Epidemiology, Outcomes, and Treatment. , 2019, Heart failure clinics.
[48] Akshay S. Desai,et al. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. , 2019, Journal of the American College of Cardiology.
[49] D. Pennell,et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial , 2019, The Lancet.
[50] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[51] Susanna Price,et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.
[52] E. Arkema,et al. Epidemiology of sarcoidosis: current findings and future directions , 2018, Therapeutic advances in chronic disease.
[53] V. Melenovský,et al. Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction , 2018, European heart journal.
[54] Sanjiv J. Shah,et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. , 2018, JACC. Heart failure.
[55] C. Poggesi,et al. Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy , 2018, Circulation. Heart failure.
[56] Jeroen J. Bax,et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology , 2018, European heart journal.
[57] G. Hindricks,et al. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany—An analysis of over 5 million patients , 2018, PloS one.
[58] C. Ayers,et al. Sex and Race Differences in Lifetime Risk of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction , 2018, Circulation.
[59] J. Mascherbauer,et al. Gender-related differences in heart failure with preserved ejection fraction , 2018, Scientific Reports.
[60] B. Gersh,et al. Women with hypertrophic cardiomyopathy have worse survival , 2017, European heart journal.
[61] M. Hanna,et al. Cardiac amyloidosis: An update on diagnosis and treatment , 2017, Cleveland Clinic Journal of Medicine.
[62] M. Elovitz,et al. Comparison of Clinical Characteristics and Outcomes of Peripartum Cardiomyopathy Between African American and Non–African American Women , 2017, JAMA cardiology.
[63] Kevin L. Thomas,et al. Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes , 2017, American heart journal.
[64] Yang Song,et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR ®) PINNACLE Registry , 2017, Journal of the American Heart Association.
[65] D. Conen,et al. Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[66] C. Rapezzi,et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.
[67] L. Lund,et al. Association between demographic, organizational, clinical, and socio‐economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry , 2017, European journal of heart failure.
[68] Jagmeet P. Singh,et al. Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator , 2017, European heart journal.
[69] G. Aurigemma,et al. Reproductive History of Women With Takotsubo Cardiomyopathy. , 2016, The American journal of cardiology.
[70] M. Maurer,et al. Transthyretin Cardiac Amyloidosis in Older Americans. , 2016, Journal of cardiac failure.
[71] J. Manson,et al. Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal Women , 2016, Circulation. Heart failure.
[72] R. Falk,et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. , 2016, Journal of the American College of Cardiology.
[73] J. Seidman,et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.
[74] Deepak L. Bhatt,et al. Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program , 2016, Circulation.
[75] J. Mascherbauer,et al. Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. , 2016, Journal of the American College of Cardiology.
[76] Sanjiv J. Shah,et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.
[77] Sanjiv J Shah,et al. Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. , 2016, Circulation. Heart failure.
[78] Dhanunjaya R. Lakkireddy,et al. Cardiac Resynchronization Therapy: US Trends and Disparities in Utilization and Outcomes , 2016, Circulation. Arrhythmia and electrophysiology.
[79] Susan Cheng,et al. Sex differences in cardiovascular ageing , 2016, Heart.
[80] R. Fischer-Betz,et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.
[81] P. Noseworthy,et al. Gender, Racial, and Health Insurance Differences in the Trend of Implantable Cardioverter‐Defibrillator (ICD) Utilization: A United States Experience Over the Last Decade , 2016, Clinical cardiology.
[82] L. Stevenson,et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial , 2016, The Lancet.
[83] P. Westermark,et al. Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition , 2015, PloS one.
[84] R. Wachter,et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy , 2015, European journal of heart failure.
[85] Frank M. Bogun,et al. Cardiac Sarcoidosis , 2015, Circulation.
[86] Jeroen J. Bax,et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. , 2015, The New England journal of medicine.
[87] Christine H Morton,et al. Pregnancy-related cardiovascular deaths in California: beyond peripartum cardiomyopathy. , 2015, American journal of obstetrics and gynecology.
[88] G. Ewald,et al. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). , 2015, Journal of the American College of Cardiology.
[89] A. Russo,et al. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). , 2015, American heart journal.
[90] J. Killian,et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. , 2015, JAMA internal medicine.
[91] J. Airaksinen,et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.
[92] W. Edwards,et al. Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.
[93] V. Roger,et al. Right Ventricular Function in Heart Failure With Preserved Ejection Fraction: A Community-Based Study , 2014, Circulation.
[94] U. Elkayam. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. , 2014, Journal of the American College of Cardiology.
[95] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[96] David G. Strauss,et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. , 2014, JAMA internal medicine.
[97] J. Healey,et al. Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middle‐Aged Adults , 2014, Journal of cardiovascular electrophysiology.
[98] Amit R. Patel,et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.
[99] P. Tchou,et al. Probability and magnitude of response to cardiac resynchronization therapy according to QRS duration and gender in nonischemic cardiomyopathy and LBBB. , 2014, Heart rhythm.
[100] S. Solomon,et al. Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction , 2014, European journal of heart failure.
[101] W. Edwards,et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.
[102] Hao Wang,et al. Role of estrogen in diastolic dysfunction. , 2014, American journal of physiology. Heart and circulatory physiology.
[103] Deepak L. Bhatt,et al. Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. , 2013, American heart journal.
[104] L. Padeletti,et al. Gender‐Related Safety and Efficacy of Cardiac Resynchronization Therapy , 2013, Clinical cardiology.
[105] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[106] Sanjiv J. Shah,et al. The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction , 2013, Current Heart Failure Reports.
[107] P. Nery,et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. , 2013, The Canadian journal of cardiology.
[108] K. Sakata,et al. Gender Differences in Patients with Takotsubo Cardiomyopathy: Multi-Center Registry from Tokyo CCU Network , 2013, PloS one.
[109] U. Sechtem,et al. Gender differences in the manifestation of tako-tsubo cardiomyopathy. , 2013, International journal of cardiology.
[110] J. Wisnivesky,et al. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. , 2013, Chest.
[111] D. Levy,et al. Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.
[112] D. Lackland,et al. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. , 2012, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[113] K. Swedberg,et al. Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator , 2012, Circulation.
[114] R. McKelvie,et al. Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction: The Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2012, Circulation. Heart failure.
[115] V. Roger,et al. Gender Differences in the Pathophysiology, Clinical Presentation, and Outcomes of Ischemic Heart Failure , 2012, Current Heart Failure Reports.
[116] Adrian F Hernandez,et al. Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.
[117] R. Wachter,et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. , 2012, Journal of the American Society of Hypertension : JASH.
[118] Kevin L. Thomas,et al. Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure: Have the Previously Observed Sex and Racial Disparities Changed Over Time? , 2012, Circulation.
[119] P. Austin,et al. Sex Differences in Implantable Cardioverter-Defibrillator Outcomes: Findings From a Prospective Defibrillator Database , 2012, Annals of Internal Medicine.
[120] Mike Kirby,et al. ESC Guidelines on the Management of Cardiovascular Diseases During Pregnancy , 2012 .
[121] S. Goland,et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. , 2011, Journal of cardiac failure.
[122] Sanjiv J. Shah,et al. Clinical Characteristics of Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction , 2011, Circulation. Heart failure.
[123] Sungha Park,et al. Sex differences in central hemodynamics and their relationship to left ventricular diastolic function. , 2011, Journal of the American College of Cardiology.
[124] L. Stevenson,et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.
[125] Kevin L. Thomas,et al. Extent of and Reasons for Nonuse of Implantable Cardioverter Defibrillator Devices in Clinical Practice Among Eligible Patients With Left Ventricular Systolic Dysfunction , 2011, Circulation. Cardiovascular quality and outcomes.
[126] J. McMurray,et al. Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.
[127] S. Mochizuki,et al. Gender and the renin–angiotensin–aldosterone system , 2010, Fundamental & clinical pharmacology.
[128] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[129] A. Natale,et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. , 2010, Heart rhythm.
[130] G. Raskob,et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.
[131] S. Goland,et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. , 2009, Journal of cardiac failure.
[132] H. Ghanbari,et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.
[133] P. Austin,et al. Evaluating sex differences in population-based utilization of implantable cardioverter-defibrillators: role of cardiac conditions and noncardiac comorbidities. , 2009, Heart rhythm.
[134] I. Piña,et al. Heart failure in women: a need for prospective data. , 2009, Journal of the American College of Cardiology.
[135] A. Lerman,et al. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. , 2008, American heart journal.
[136] K. Schulman,et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. , 2007, JAMA.
[137] M. Hudson,et al. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure — A population study , 2007, European journal of heart failure.
[138] Anne L. Taylor,et al. Outcomes by gender in the African-American Heart Failure Trial. , 2006, Journal of the American College of Cardiology.
[139] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[140] M. Drazner,et al. Women Have Higher Left Ventricular Ejection Fractions Than Men Independent of Differences in Left Ventricular Volume: The Dallas Heart Study , 2006, Circulation.
[141] D. Kass,et al. Age- and Gender-Related Ventricular-Vascular Stiffening: A Community-Based Study , 2005, Circulation.
[142] M. Link,et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.
[143] U. Elkayam,et al. Pregnancy-Associated Cardiomyopathy: Clinical Characteristics and a Comparison Between Early and Late Presentation , 2005, Circulation.
[144] C. O'connor,et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. , 2004, Journal of the American College of Cardiology.
[145] C. Yancy,et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. , 2003, Journal of the American College of Cardiology.
[146] Paul G Shekelle,et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.
[147] G. Biondi-Zoccai,et al. Reduced post-infarction myocardial apoptosis in women: a clue to their different clinical course? , 2003, Heart.
[148] Harlan M Krumholz,et al. Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.
[149] C. Fonseca,et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study , 2002, European journal of heart failure.
[150] I. Piña,et al. Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) , 2002, Circulation.
[151] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[152] T. Simon,et al. Sex Differences in the Prognosis of Congestive Heart Failure: Results From the Cardiac Insufficiency Bisoprolol Study (CIBIS II) , 2001, Circulation.
[153] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[154] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[155] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[156] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[157] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .
[158] A. Beale,et al. Sex Differences in Heart Failure with Preserved Ejection Fraction Therapy: Potential Mechanisms and Clinical Implications , 2020 .
[159] G. Lewis,et al. Sex Differences in Cardiometabolic Traits and Determinants of Exercise Capacity in Heart Failure With Preserved Ejection Fraction. , 2019, JAMA cardiology.
[160] C. Albert,et al. Atrial Fibrillation and Heart Failure in Women. , 2019, Heart failure clinics.
[161] U. Elkayam,et al. Peripartum Cardiomyopathy. , 2016, Circulation.
[162] K. Stergiopoulos,et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.
[163] F. Zannad. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms , 2011 .
[164] B. Pitt,et al. EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .